Zepbound Pediatric (Under 12) Dosing: What Parents and Clinicians Need to Know

Is Zepbound Approved for Children Under 12?

Zepbound (tirzepatide) has no FDA-approved indication for any patient under 18 years old. The FDA granted approval for chronic weight management in adults with a body mass index (BMI) of 30 kg/m or greater, or 27 kg/m or greater with at least one weight-related comorbidity, in November 2023. That labeling explicitly excludes pediatric populations. No weight-based or age-adjusted pediatric dose exists in the current prescribing information, and off-label use in children under 12 is not endorsed by the American Academy of Pediatrics (AAP), the Pediatric Endocrine Society (PES), or the Obesity Medicine Association (OMA).

The absence of an approved dose is not a regulatory technicality. Children under 12 have distinct pharmacokinetic profiles, ongoing hypothalamic-pituitary-gonadal axis development, and growth-plate activity that make adult dosing assumptions unsafe to transfer without dedicated trials. Subcutaneous absorption rates, volume of distribution, and renal clearance of peptide-based drugs all shift considerably across childhood. Until Eli Lilly completes and publishes pediatric studies, no clinician can calculate a validated weight-based tirzepatide dose for a child in this age group.

Why There Is No Approved Pediatric Dose Yet

Regulatory agencies require drug manufacturers to conduct pediatric-specific pharmacokinetic (PK) and safety studies under the Pediatric Research Equity Act (PREA) for drugs that target conditions affecting children. Eli Lilly submitted a pediatric study plan to the FDA, which is a standard requirement, but the studies are ongoing. The current registered trial (NCT05765097) evaluates tirzepatide's safety, tolerability, and pharmacokinetics in children ages 6 to 11 with obesity. As of July 2025, enrollment is active but no efficacy or safety data have been publicly reported.

PREA studies proceed in phases. A Phase 1 PK study typically runs 12 to 24 months and involves 20 to 60 participants. Dose-finding must precede any efficacy trial. Given that timeline, a labeled pediatric dose for the 6-to-11 age band is unlikely before late 2026 at the earliest, and the under-6 group would require a separate study entirely.

The FDA's Pediatric Advisory Committee guidance on GLP-1 and dual GIP/GLP-1 receptor agonists emphasizes that the gut hormone system matures substantially between infancy and mid-adolescence. This is relevant because tirzepatide activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, a dual mechanism that has no precedent in approved pediatric obesity pharmacotherapy as of this writing.

What the Adult Evidence Shows (And Why It Cannot Simply Transfer)

SURMOUNT-1 (N=2,539), published in the New England Journal of Medicine in 2022, remains the foundational efficacy trial for tirzepatide in obesity [1]. Adults with a BMI of 30 or greater, or 27 or greater with at least one comorbidity, were randomized to tirzepatide 5 mg, 10 mg, or 15 mg once weekly or placebo for 72 weeks. The 15 mg group achieved 20.9% mean body-weight loss versus 3.1% in the placebo group (P<0.001). The 10 mg group lost 19.5%, and the 5 mg group lost 15.0%. Those numbers are striking. They come from adults aged 18 and older with fully developed organ systems, defined comorbidity profiles, and adult-calibrated metabolic set points.

Applying a weight-scaled version of these doses to a 9-year-old with obesity would be pharmacologically unsupported for several concrete reasons. First, GIP receptor density and signaling in pre-pubertal children differs from adult patterns, and the clinical effect of dual agonism at that stage is unknown. Second, nausea, vomiting, and appetite suppression at doses effective in adults could produce caloric restriction severe enough to impair linear growth in a child whose bone age has not closed. Third, the SURMOUNT-1 safety profile, which included gallbladder disease in 2.0% of the tirzepatide arm, pancreatitis signals, and thyroid C-cell findings in rodents, has not been characterized for developing endocrine tissue. No pediatric risk-benefit ratio can be calculated without pediatric data.

The Only FDA-Approved GLP-1 Option for Near-Pediatric Ages

Semaglutide 2.4 mg (Wegovy) received FDA approval in December 2022 for adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex). This approval was based on the STEP TEENS trial (N=201), which showed a 16.1% reduction in BMI at 68 weeks versus a 0.6% increase in the placebo group [2]. That approval covers ages 12 to 17 only. No GLP-1 or dual-agonist drug currently holds FDA approval for obesity treatment in children under 12.

For children ages 10 and older with type 2 diabetes (not obesity as a primary indication), liraglutide 1.8 mg (Victoza) is FDA-approved, and semaglutide 0.5 mg to 1 mg (Ozempic) is approved for type 2 diabetes from age 10 upward [3]. These glycemic indications are distinct from the chronic weight-management indication that Zepbound carries. A child under 12 with obesity but without type 2 diabetes has no FDA-approved GLP-1 class drug available.

Current Standard of Care for Obesity in Children Under 12

The AAP published a comprehensive Clinical Practice Guideline in January 2023 that, for the first time, recommended early, intensive intervention for pediatric obesity rather than a "watchful waiting" approach [4]. The guideline's pharmacotherapy section states: "Clinicians should offer adolescents 12 years and older with obesity weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment." The guideline does not recommend pharmacotherapy for children under 12 as a routine approach.

For the under-12 group, the evidence base points firmly toward structured behavioral and lifestyle intervention. The gold standard is intensive health behavior and lifestyle treatment (IHBLT), defined as at least 26 contact hours with a multidisciplinary team over a 3-to-12-month period. Dietary guidance follows age-appropriate caloric targets, not adult-calibrated restriction. Physical activity goals align with the Physical Activity Guidelines for Americans, which specify 60 minutes of moderate-to-vigorous activity daily for children aged 6 to 17 [5].

Metformin is sometimes used off-label in children under 12 with insulin resistance or early metabolic dysfunction, but its effect on BMI is modest. A Cochrane review of metformin in pediatric obesity (2016, updated evidence through 2021) found mean BMI reductions of approximately 1.0 to 1.4 kg/m versus placebo, far below the reductions seen with GLP-1 class agents in adults [6]. Orlistat is FDA-approved from age 12, not age 11 or younger.

How Tirzepatide Dosing Works in Adults (Reference for Future Pediatric Context)

Understanding the adult titration schedule matters for clinicians who will eventually manage pediatric patients if approval comes through. The current FDA-approved adult starting dose is 2.5 mg subcutaneous once weekly for 4 weeks. The dose escalates by 2.5 mg every 4 weeks as tolerated, through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to the maximum maintenance dose of 15 mg once weekly. The full titration from start to maximum dose takes approximately 20 weeks.

Tirzepatide is supplied as a single-dose autoinjector pen in six strengths: 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL. Each pen delivers a fixed volume. There is no approved liquid formulation that would permit weight-based micro-dosing for small children, which is another practical barrier to pediatric use even before the regulatory question is resolved.

Common adult adverse effects that a pediatric study must characterize include nausea (occurring in approximately 30.5% of the 15 mg group in SURMOUNT-1), diarrhea (22.1%), vomiting (14.9%), and constipation (11.8%) [1]. In a child aged 6 to 11 with a lower body weight, those gastrointestinal effects could translate to proportionally greater nutritional disruption and dehydration risk. Renal function monitoring and hydration protocols for this age group will need to be defined by the pediatric trials.

What Families and Prescribers Should Do Now

Families seeking obesity treatment for children under 12 should work with a board-certified pediatric obesity medicine specialist or a pediatric endocrinologist. The first-line intervention for this age group remains IHBLT, and access has improved since CMS expanded coverage for intensive behavioral counseling in pediatric beneficiaries following the AAP 2023 guideline release.

Prescribers should not write tirzepatide prescriptions for patients under 18 for the obesity indication. Compounded tirzepatide, which is legally available from 503B outsourcing facilities during shortage periods, carries the same absence of pediatric data and should not be administered to children under 12 under any circumstances. The FDA's position, stated in a 2024 guidance update, is that compounded versions of approved drugs do not inherit the approved drug's safety profile and are subject to additional scrutiny in vulnerable populations including children [7].

For families interested in clinical trials, NCT05765097 is actively recruiting at selected U.S. sites. Eligibility requires age 6 to 11, a BMI at or above the 95th percentile for age and sex, and no prior GLP-1 or GIP receptor agonist use. Clinicaltrials.gov can be searched for the NCT number to find enrolling sites and contact information.

Monitoring Parameters If Future Approval Occurs

When (and if) a pediatric label for tirzepatide in the under-12 group is granted, clinical monitoring will likely be more intensive than adult protocols. Based on the monitoring framework used in STEP TEENS for semaglutide, reasonable expectations include height and weight measured at every visit to calculate BMI percentile, linear growth velocity tracked against age-sex growth charts, HbA1c and fasting glucose at baseline and every 12 weeks, lipid panel at baseline and every 24 weeks, and thyroid palpation with TSH measurement given the rodent C-cell signal.

Pubertal staging (Tanner scale) should be documented at baseline and at least every 6 months, since GLP-1 receptors are expressed in hypothalamic nuclei involved in pubertal timing. This is not a concern that has emerged in the adult or adolescent data, but prudent pediatric practice requires tracking it prospectively.

Bone density monitoring may also be added given that caloric restriction during periods of rapid bone accrual (ages 6 to 12) could affect peak bone mass. The STEP TEENS trial did not show bone density deficits at 68 weeks in the 12-to-17 cohort, but a longer follow-up and a younger cohort would warrant closer attention [2].

The Regulatory Path Forward

Eli Lilly must submit results from NCT05765097 and any subsequent Phase 2/3 pediatric efficacy trial to the FDA before a labeled pediatric dose can appear in the prescribing information. The FDA's Office of Pediatric Therapeutics reviews this data under PREA and may convene an advisory committee before issuing a decision.

If Phase 1 PK data from the 6-to-11 cohort are submitted in late 2025, the FDA's standard review timeline of 10 to 12 months would place a decision in 2026 to 2027. A priority review designation, which requires evidence of serious unmet need, could shorten that window by 4 months. Pediatric obesity in the 6-to-11 group, where no pharmacologic option is currently approved, may qualify. That determination rests with the FDA.

Physicians who want to stay current should monitor the FDA Drugs@FDA database and the Eli Lilly pipeline page for label updates. The current package insert for Zepbound, accessible at FDA.gov, should be the reference document for any prescribing decision and will reflect any new approved use immediately upon labeling change [8].